Integrative computational evaluation of genetic markers for Alzheimer's disease

Zhe Li a,b,1, ZhenZhen Xiong c,1, Lydia C. Manor d, Hongbao Cao e,f, Tao Li a,⇑

a The Mental Health Center and the Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
b The Mental Rehabilitation Center, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China
c School of Nursing, Chengdu Medical College, Chengdu, Sichuan 610083, China
d Department of Bioinformatics, American Informatics Consultant LLC, Rockville, MD 20852, USA
e Unit on Statistical Genomics, National Institute of Mental Health, NIH, Bethesda 20892, USA
f Department of Genomics Research, R&D Solutions, Elsevier Inc., Rockville, MD 20852, USA

1 These authors contributed equally to this work.

Abstract

Recent studies have reported hundreds of genes linked to Alzheimer’s Disease (AD). However, many of these candidate genes may be not identified in different studies when analyses were replicated. Moreover, results could be controversial. Here, we proposed a computational workflow to curate and evaluate AD related genes. The method integrates large scale literature knowledge data and gene expression data that were acquired from postmortem human brain regions (AD case/control: 31/32 and 22/8). Pathway Enrichment, Sub-Network Enrichment, and Gene-Gene Interaction analysis were conducted to study the pathogenic profile of the candidate genes, with 4 metrics proposed and validated for each gene. By using our approach, a scalable AD genetic database was developed, including AD related genes, pathways, diseases and info of supporting references. The AD case/control classification supported the effectiveness of the 4 proposed metrics, which successfully identified 21 well-studied AD genes (i.e. TGFB1, CTNNB1, APP, IL1B, PTGS2, IL6, VEGFA, SOD1, AKT1, CDK5, TNF, GSK3B, TP53, CCL2, BDNF, NGF, IGF1, SIRT1, AGER and TLR) and highlighted one recently reported AD gene (i.e. ITGB1). The computational biology approach and the AD database developed in this study provide a valuable resource which may facilitate the understanding of the AD genetic profile.

Keywords:
Alzheimer’s disease
ResNet database
Pathway enrichment analysis
Sub-network enrichment analysis
Gene-gene interaction analysis

1. Introduction

Alzheimer’s disease (AD) is a chronic neurodegenerative disease that usually onsets slowly and progresses more rapidly over time (Burns and Iliffe, 2009). It is the leading cause of dementia, beginning with impaired memory, and most often onsets in people over 65 years of age (Mendez 2012). The global prevalence of AD as of 2015 was estimated to be as high as 48 million people worldwide (World Health Organization, 2015). Although the cause of most Alzheimer’s cases largely remains unknown, about 70% of the risk is believed to come from a large network of genes (Ballard et al., 2011). As such, researches into the causes of AD are currently being explored.

In recent years, an increased number of genetic researches have been conducted revealing over a thousand altered genes linked to AD. For example, increased GSK3B activity and decreased phosphorylation of the gene have been repeatedly observed in AD cases (Cole et al., 2007; Koedam et al., 2013; Xu et al., 2016). Significantly increased expression levels of TP53, PTGS2 and TGFBI were suggested by many independent studies to be associated with AD (Cenini et al., 2008; Lanni et al., 2012; Ramalho et al., 2008; Yoo et al., 2008; Wang et al., 2014; Luo et al., 2006). Observations from these previous studies are valuable in studying the genetic basis of the pathogenic development of the disease.

However, approximately one third of these AD-gene linkages were reported once with no further replication, and over 60% were supported by no more than three citations. Moreover, most of
these studies had small sample sizes that were more susceptible to noise. Additionally, due to the variation in data collection and processing approaches, results from different studies were not always consistent. Meanwhile, there are dozens of new AD risk genes being reported every year, posing an increased need for further validation of these candidate genes to AD. While biological experiments were effective towards this validation task, they could be very costly. To address this issue, we propose a computational biology approach for a systematic evaluation of these AD candidate genes.

In recent years, Pathway Studio ResNet relation data have been widely used to study modeled relationships between proteins, genes, complexes, cells, tissues and diseases (http://pathwaystudio.gousinfo.com/Mendeley.html). In this study, we integrated large scale AD related ResNet literature knowledge data, independent gene expression data and related pathway/network information to study the functional profile of a large gene pool that has been reported to be linked to AD. The purpose of the study is to provide an easy-update computational evaluation workflow, through which an AD genetic database (AD_GD) could be generated to present a weighted landscape view of the genetic basis underlying the pathogenic development of AD. Our results support the hypothesis that AD candidate genes are functionally linked to each other, forming a large genetic network to regulate the pathogenic development of AD through multiple pathways.

2. Materials and methods

Fig. 1 presents the diagram of the proposed computational gene marker evaluation system, with detailed descriptions in the following sub-sections. Using our approach, a genetic database (AD_GD) was developed and deposited into an open source ‘Bioinformatics Database’ online available at http://database.gousinfo.com, including 1699 genes (with metric scores), 151 pathways and 114 diseases that are linked to AD. Also included in AD_GD are information of 27000+ supporting references for AD-gene relationships, including the titles and relevant sentences where the relations were identified. The AD_GD database is scalable and will be updated monthly or upon request using our approach.

2.1. ResNet literature knowledge data

ResNet relation data (AD-Gene) were acquired from the Pathway Studio ResNet Mammalian database (http://pathwaystudio.gousinfo.com/ResNetDatabase.html) updated November 2016. The ResNet Mammalian database are a group of real-time updated literature knowledge databases, including curated signaling, cellular processes and metabolic pathways, ontologies and annotations, as well as molecular interactions and functional relationships (http://pathwaystudio.gousinfo.com/ResNetDatabase.html). Modeled relation data are extracted from the 41M+ references covering entire PubMed abstracts and Elsevier and third party full text journals. The ResNet database employs an automated natural language processing-based information extraction system, MedScan, with precision of over 91% (Daraselia et al., 2004). Each relationship within the database is supported with one or more references. By far, Pathway Studio ResNet Databases is the largest database among known competitors in the field (Lorenzi et al., 2014).

2.2. Enrichment and gene-gene interaction analysis

Pathway enrichment analysis (PEA) and sub-network enrichment analysis (SNEA) (http://pathwaystudio.gousinfo.com/SNEA.pdf) was conducted using Pathway Studio to identify genetic pathways and diseases potentially linked to AD (Sivachenko et al., 2007). Furthermore, a pathway based gene-gene interaction (GGI) analysis was conducted to generate weighted edges/linkage between genes. The weight of an edge is the number of pathways where both nodes were included.

2.3. Metrics analysis

For the gene network built through the aforementioned steps, 4 metrics were proposed for each node/gene, including 2 literature based metric scores (RScore and AScore), and 2 enrichment based metric scores (PScore and SScore). The logic is that, a gene is likely linked to AD if it satisfies one or more of the following conditions: the gene has been frequently observed in independent studies to be associated with AD (high RScore), plays roles within multiple pathways associated with AD (high PScore), and demonstrates strong functional linkage to many of other genes associated with AD (high SScore). Additionally, an AScore was proposed to present the history of each AD-gene relation. The detailed definitions of the proposed metrics are described as follows.

2.3.1. Two literature metrics

The reference score (RScore) of a gene is defined as the reference number underlying a gene-disease relationship, as shown in Eq. (1).

\[ \text{RScore} = \sum \text{reference number} \]

The reference score (RScore) of a gene is defined as the reference number underlying a gene-disease relationship, as shown in Eq. (1).
\[ \text{Rscore} = \text{The number of references underlying a realtionship} \]

The age score (AScore) of a gene is defined as the earliest publication age of a gene-disease relationship, as shown in Eq. (2).

\[ \text{AScore} = \max_{1 \leq i \leq n} \text{ArtilcePubAge}_i \]

where \( n \) is the total number of references supporting a gene-disease relation, and

\[ \text{ArticlePubAge} = \text{current date} - \text{publication date} + 1 \]

\[ \text{SScore} = \sum_j \chi_j = \text{number of nodes directly linked with current node} \]

where \( n \) is the total number of nodes, and \( j \) represents all other nodes within the network; \( x \) is the adjacency matrix, in which the cell \( x \) is 1 if the jth node is connected with the current node, other with is 0.

Given a disease is associated with a set of genetic pathways \( \mathcal{R} \), we define the \( \text{PScore} \) for the gene as Eq. (5).

\[ \text{PScore}_k = \text{The number of pathways from} \mathcal{R} \text{including the} k \text{th gene} \]

2.4. Validation using independent gene expression data

We hypothesized that significant AD related genes should contribute to distinguishing AD patients from healthy controls. To validate the effectiveness of the selected genes and the proposed metrics, we performed a Euclidean distance-based multivariate date sets (NCBI GEO: GSE29378 and GSE28146), followed by a leave-one-out (LOO) cross validation, using the overall gene set and the sub-sets selected by different scores as tentative markers. In each run of LOO, gene expression data of one subject is used for testing and the rest for training. A permutation of 5000 runs was then conducted to test the hypothesis that a randomly selected gene set in same size can reach equal or higher classification accuracy (CR).

For dataset GSE29378, RNA expression profile of 64 subjects (AD case/control: 31/32) were obtained from 60 \( \mu \text{m} \) sections of frozen human hippocampus using scalpel dissection. Of the 1699 genes evaluated, 1605 were included in the database. For GSE28146, brain sections from a total of 30 subjects were analyzed (case/control: 22/8), with 1621 out of 1699 genes included.

3. Results

3.1. AD genes for evaluation

AD-Gene literature knowledge data analysis identified 1699 AD genes, supported by 27128 scientific articles (AD_GD \( \rightarrow \) Related Genes and AD_GD \( \rightarrow \) References for Disease-Gene Relation). A scalable genetic database, AD_GD, was developed through our study, which is online available at ‘Bioinformatics Database’ (http://database.gousinfo.com).

Of the 1699 genes, 644 (37.90\%) have been reported with one reference (RScore = 1), 262 (15.42\%) with 2, 181 (10.65\%) with 3, and 433 (25.49\%) with more than 5 references, as shown in Supplementary Fig. S1(a). Publication date statistics of the 27128 supporting references are presented in Supplementary Fig. S1(b), with novel genes reported in each year (Supplementary Fig. S1(c)). To note, these articles have an average publication age of only 7.4 years, indicating that most of the articles were published in recent years.

3.2. Enrichment analysis results

PEA showed that, 1453 out of 1699 genes got significantly enriched within 151 AD candidate pathways/gene sets (p-values < 1e-15, q = 0.001 for FDR; AD_GD \( \rightarrow \) Related Pathways). Not surprisingly, aging (GO: 0016280; overlap 140 genes; q-value = 2.28E-84) is the top one enriched gene group. In addition, 11 pathways/groups were related to the neuronal system (619 unique genes) (Gong and Lippa, 2010; Marcello et al., 2012), 10 to cell growth and proliferation (441 unique genes) (Holman et al., 2015; Li and Yao, 2013), 8 to cell apoptosis (452 unique genes) (Behl, 2000), 5 to protein phosphorylation (246 unique genes) (Shapiro et al., 1991), 2 to protein kinase (209 unique genes) (Martin et al., 2013), 3 to brain function/development (99 unique genes) (Llorente-Vizcaino and Cejudo-Bollivar, 2001), and 2 to immune system (268 unique genes) (Heneka et al., 2001). Due to lack of space, we only present the top 10 pathways enriched in Table 1 (p-value < 2.6e-55, including 755 out of 1699 genes).

A SNEA was also performed to identify the pathogenic significance of the reported genes to other disorders which are potentially related to AD. Interestingly, besides neuropathic related diseases (e.g., Parkinson’s disease and Schizophrenia) and some types of cancers (e.g., breast cancer), AD seems to share major gene overlaps with many blood related diseases (e.g., diabetes mellitus, obesity, type 2 diabetes, atherosclerosis, ischemia, myocardial infarction, hyperglycemia and stroke). The full list of 113 disease related sub-networks enriched with p-value < 1e-150 (q = 0.001 for FDR; 1625 out of 1699 genes enriched; see AD_GD \( \rightarrow \) Related Diseases).

3.3. GGI results

Fig. 2 presents the genetic network for AD, which was built through GGI analysis. The nodes of the network are 1453 out of 1699 genes that were enriched within the 151 AD target pathways. There were 319206 edges within the network, the weight of which are the numbers of pathways shared by the corresponding pair of nodes. The average node strength (sum of the number of genes directly connected) of the network was 219.69, and the node strength for the 246 unconnected genes was signed with 0.

Along with GGI, SScore and PScore were calculated for each gene (AD_GD \( \rightarrow \) Related Genes). The value of a PScore represents how many AD candidate pathways involve the gene, and an SScore represents how strong of a gene associated with other genes within the network.

3.4. Validation results

We hypothesized that, if our selected gene set (1669 genes) and the top genes selected by the proposed metric scores are significant to the pathogenesis of AD, they should lead to significant higher classification accuracy comparing to randomly selected genes. To test the hypothesis, classification and LOO cross validation were conducted on two independent public RNA expression dataset (NCBI GEO: GSE29378 and GSE28146), followed by a permutation test of 5000 runs.

For the LOO cross validation, the 1669 genes were first ranked by different metric scores, then the top \( n (n = 1, 2, \ldots) \) genes were
used as input variables for classification and LOO cross validation. Table 2 and Fig. 3 presents the results with the maximum classification ratios (CRs) marked at the position of corresponding number of genes.

From Fig. 3 we see that the top genes selected by different scores (in descending order) can lead to the highest classification accuracies, which are significantly higher than the average CRs of randomly selected gene set in same size, while adding more genes with lower score may not necessarily lead to improved CRs.

### 3.5. Cross metrics analysis

Results from AD case/control classification (Table 2 and Fig. 3) showed that, the top genes selected using each of the four proposed metrics led to significantly higher CR compared to randomly selected gene sets, demonstrating the effectiveness of the proposed metrics. Therefore, it is worthy to study the overlaps among these top genes. Cross metrics analysis of the top 5% (86 genes, corresponding to the number of genes reported this year, 2016) of 1699 genes selected using different scores showed that (see Veen Table 2 Permutation test on top genes corresponding to highest CRs.

| Pathway/gene set name | GO ID | # of Entities | Overlap | p-value | Jaccard similarity |
|-----------------------|-------|---------------|---------|---------|--------------------|
| Aging                 | 0016280 | 254           | 140     | 2.28E-84 | 0.077              |
| Neuronal cell body    | 0043025 | 466           | 172     | 4.7E-72  | 0.086              |
| Neuron projection     | 0043005 | 378           | 153     | 2.8E-70  | 0.079              |
| Response to lipopolysaccharide | 0032496 | 252     | 126     | 4.9E-69  | 0.069              |
| Response to hypoxia   | 0001666 | 259           | 127     | 8.11E-68 | 0.069              |
| Response to organ cyclic compound | 0014070 | 253     | 122     | 1.75E-64 | 0.067              |
| Response to ethanol   | 0017036 | 161           | 94      | 4.21E-59 | 0.053              |
| Negative regulation of apoptotic process | 0006916 | 650     | 187     | 1.21E-56 | 0.086              |
| Perinuclear region of cytoplasm | 0048471 | 688     | 188     | 2.11E-55 | 0.085              |
| Axon                  | 0030424 | 318           | 125     | 2.56E-55 | 0.066              |

For each gene set, the p-value was calculated using Fisher’s-Exact test against the hypothesis that a randomly selected gene group of same size (1669) can generate a same or higher overlap with the corresponding gene set (q = 0.001 for FDR correction). The Jaccard similarity \( (\frac{|A \cap B|}{|A \cup B|}) \) is a statistic used for comparing the similarity and diversity of sample sets, which is defined by \( J(A, B) = \frac{|A \cap B|}{|A \cup B|} \) where A and B are two sample sets.

For each gene set, the p-value was calculated using Fisher’s-Exact test against the hypothesis that a randomly selected gene group of same size (1669) can generate a same or higher overlap with the corresponding gene set (q = 0.001 for FDR correction). The Jaccard similarity \( (\frac{|A \cap B|}{|A \cup B|}) \) is a statistic used for comparing the similarity and diversity of sample sets, which is defined by \( J(A, B) = \frac{|A \cap B|}{|A \cup B|} \) where A and B are two sample sets.

Fig. 2. Gene-gene interaction network for AD. The network contains 1453 out of 1669 genes AD target genes that enriched within the 151 AD target pathways. The weight of an edge between two nodes is the number of pathways shared by both nodes. The larger the size of a node, the larger the number of AD candidate pathways including the gene (high PScore); the brighter the color, the larger number of AD candidate genes associated with gene (high SScore). 216 out of 1669 genes were not included in the network as they were not enriched within the top 151 AD candidate pathways.
diagram at Supplementary Fig. S2), there was strong overlap between PScore group and SScore group (63/86). Among these 63 genes, 21 were also identified to be within RScore group, including TGFβ1, CTNNB1, APP, IL1B, PSEN1, PTGS2, IL6, VEGFA, SOD1, AKT1, CDK5, TNF, GSK3B, TP53, CCL2, BDNF, NGF, IGF1, SIRT1, AGER and TLR4, with RScore = 542 ± 16 references, PScore = 29 ± 6 pathways, SScore = 969 ± 85 connected genes. Network analysis using Pathway Studio showed that, these 21 genes also demonstrated strong correlation with the top disorders that are linked to AD (Fig. 4, highlighted in red). The genes related to these diseases present significant overlap with these genes linked to AD (see AD_GD → Related Diseases). On the other hand, only one gene, ITGB1, was identified to be the overlap of AScore, PScore and SScore groups (Fig. 4, highlighted in yellow), which also linked to several other diseases (e.g., diabetes, stroke and breast cancer) that are genetically linked to AD.

Fig. 3. Validation of different metrics through a LOO cross validation. (a) Results from GSE29378; (b) Results from GSE28146. Mean of CRs by randomly selected genes are displayed in a dash-grey line (Legend: Random). The maximum CR by different metrics are presented at the corresponding positions.

Fig. 4. AD genes selected by cross metrics analysis and their relation with other diseases. The 21 genes that were overlap in RScore, PScore and SScore groups are highlighted in green; Gene ITGB1 that was the overlap in AScore, PScore and SScore groups and is highlighted in yellow. The network was built using the ‘network building’ module of Pathway Studio.
4. Discussion

Recent studies proposed over a thousand of AD risk genes with dozens of novel targets identified each year. However, over half of these AD target genes were lack of replication and results were not always consistent, posing an increasing need of a systematic evaluate approach to test the significance of these genes as a network to AD. In this study, we integrated large scale literature knowledge data, gene expression data and related pathways and disease-sub networks to evaluate 1669 AD candidate genes. Four metric scores have been proposed and validated. A scalable genetic database, AD_GD, was developed through our study, which is online available at ‘Bioinformatics Database’ (http://database.gousinfo.com).

PEA results showed that most genes within the network (1453 out of 1699) were significantly enriched (FDR corrected p-value < 1e−15) in the pathways previously implicated with AD, including pathways/groups related to aging, neuronal system pathways, cell growth and proliferation, cell apoptosis, protein phosphorylation brain function/development and immune system (Gong and Lippa, 2010; Marcello et al., 2012; Hofman et al., 2015; Li and Yao, 2013; Behl, 2000; Shapiro et al., 1991; Martin et al., 2013; Llorente-Vizcaíno and Cejudo-Bolívar, 2001; Heneka et al., 2001). These observations support the hypothesis that, most of the AD target genes are functionally linked to each other and play roles within multiple pathways associated with AD.

In addition to PEA, we performed a SNEA, which can provide high levels of confidence when interpreting experimentally-derived genetic data against the background of previously published results (http://pathwaystudio.gousinfo.com/SNEA.pdf). SNEA results demonstrated that over 95% (1625) of the 1669 AD genes were as well identified as causal genes for other disorders that were linked to AD (AD_GD – Related Diseases).

For a quantitative measure of the significance of these 1669 AD candidate genes, we proposed 4 metrics: (1) publication frequency (RScore), (2) novelties (AScore), (3) Number of associated AD candidate pathways (PScore), and (4) Network centrality (SScore). We hypothesized that if a gene satisfies one or more of the following conditions, it has high possibility to be linked to AD: The gene is frequently identified by independent studies to be linked to AD (high RScore), plays roles within multiple AD pathways (high PScore), and is functionally linked to multiple AD genes (high SScore).

The effectiveness of our 4 proposed metrics were supported by the AD case/control classification study using two independent gene expression data sets (GSE29378 and GSE28146). Results of the LOO cross validation and permutation process showed that, the top genes by the 4 proposed metrics can lead to significantly higher classification ratio than using randomly selected gene sets (Table 2 and Fig. 3). While using the identified gene set as a whole (1605 and 1621 out of 1669 for GSE29378 and GSE28146, respectively) showed no significant efficiency in terms of AD prediction (permutation p-value > 0.9; see Table 2), suggesting the necessity of using our network metrics for further analysis of the candidate AD genes when dealing with specific experiment data. Notably, for each score, the number of top genes corresponded to the maximum CRs for the two data sets were different. This may reflect the group-wise variation in terms of sample size (63 vs. 30) and clinical parameter dissimilarities (e.g., age, gender). The difference may be also caused by the unique variation of different subjects’ genome in case of AD.

Cross metrics analysis showed that 21 genes were overlapped within RScore, SScore and PScore groups (Fig. 4, highlighted in green). These genes were frequently identified by different studies to be linked to AD (RScore = 542 ± 16 references), play roles within multiple AD candidate pathways (PScore = 29 ± 6 pathways), and demonstrate strong network centrality (SScore = 969 ± 85 direct gene connections). Therefore, our results suggest that they are among the top AD risk genes that likely pose biological significance with the disease. As a matter of fact, these genes were also identified to play role within many other disorders that were linked to AD, such as diabetes mellitus, obesity, Parkinson’s disease, Schizophrenia, and breast cancer (Fig. 4). These results support the effectiveness of the proposed metric scores in the identification of top genes for AD.

Additionally, there was one newly reported gene, ITGB1 (AScore = 1), also demonstrated high SScore and PScore (Fig. 4, highlighted in yellow). Although ITGB1 were not frequently replicated in their association with AD (RScore = 1 reference), and presented less relationships with other AD related mental disorders, it demonstrated high interaction with other genes within the genetic network (SScore = 1050 directly connected genes) and play role within multiple pathways implicated with AD (PScore = 28 pathways). Therefore, our study suggests that it may be worthy of further study. In fact, activation of integrin β1 (ITGB1) has been reported to regulate the synthesis of enterovirus 71-induced and NADPH oxidase-driven reactive oxygen species (ROS) (Tung et al., 2011), which are closely involved in pathogeneses of AD (Aliev et al., 2003). It also revealed that adhesion of Hela cells to β1 integrin clustering can increase the release of arachidonic acid (Xu and Clark, 1997) that has therapeutic functions against AD (Huang and Cheung, 2011). These findings support our observation that ITGB1 may play roles for pathogenic development of AD, demonstrating the effectiveness of our proposed PScore and SScore in identifying novel genes for the disease. To note that, although in this study we evaluated 1669 known AD candidate genes acquired from ResNet database, which already received literature support for their association with AD, our proposed PScore and SScore can be applied to any given genes and therefore could be used for evaluation and discovery of novel target genes for AD.

The genetic database built through our approach, namely AD_GD, is scalable and can be automatically updated using the computational workflow proposed in this study. Any novel AD-gene relationships can be added to update the database. Moreover, further network analysis with more experiment data may extract additional meaningful features that can be added into our proposed system to gain improved evaluation of existing and/or novel AD genes.

To our knowledge, this is the first study integrating large scale literature knowledge data, experiment data and related pathway/network data for a systematical evaluation of AD candidate genes. The computational biology approach of this study provides a comprehensive weighted genetic network and genetic database for AD, which may help in the evaluation and prioritization of AD genes for further study in the field.

Acknowledgement

We would like to thank Mckenzie Ritter for her contribution to the English writing of this manuscript. This work was partly funded by National Nature Science Foundation of China (81130024 and 81630030, Tao Li), National Key Technology R & D Program of the Ministry of Science and Technology of China during the 12th Five-Year Plan (2012BA011B06, Tao Li), National Key Research and Development Program of the Ministry of Science and Technology of China (2016YFC0904300, Tao Li), Science and Technology Department of Sichuan Province of China (2017SZ0049, Zhe Li; 2018ZR0216, Zhenzhen Xiong), and Health and Family Planning Commission of Sichuan Province of China (17J080, Zhe Li). The Fundamental Research Funds for The Central Universities of China (2017SCU11072, Zhe Li).
Conflict of interest

The author HC is with Elsevier Inc., the company that owns the software Pathway Studio used in this study.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.sjbs.2018.05.019.

References

Aliev, G., Obrenovich, M.E., Smith, M.A., Perry, G., 2003. Hypoperfusion, mitochondria failure, oxidative stress, and alzheimer disease. J. Biomed. Biotechnol. 2003 (3), 162–163.

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., Jones, E., 2011. +UVA treatment increases the degree of unsaturation of microalgal fatty acids and total carotenoid content in Nitzschia closterium (Bacillariophyceae) and Phaeodactylum tricornutum (Chrysophyceae). Food Chem. 129 (3), 783–791.

Huang, J.J., Cheung, P.C., 2011. +UVA treatment increases the degree of unsaturation of microalgal fatty acids and total carotenoid content in Nitzschia closterium (Bacillariophyceae) and Thalassiosira zhangjiangensis (Chrysophyceae). Food Chem. 129 (3), 783–791.

Shapiro, I.P., Masliah, E., Saitoh, T., 1991. Altered protein tyrosine phosphorylation in Alzheimer’s disease. J. Neurochem. 56 (4), 1154–1162.

Heneka M.T., Golenbock D.T., Latz E., 2001. Innate immunity in Alzheimer’s disease. Ann. N.Y. Acad. Sci. 945, 134–144.

Lanni, C., Racchi, M., Memmo, M., Govoni, S., Uberti, D., 2012. p53 at the crossroads between cancer and neurodegeneration. Free Radic. Biol. Med. 52 (9), 1727–1733.

Obrenovich, M.E., Smith, M.A., Perry, G., 2003. Hypoperfusion, mitochondria failure, oxidative stress, and alzheimer disease. J. Biomed. Biotechnol. 2003 (3), 162–163.

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., Jones, E., 2011. +UVA treatment increases the degree of unsaturation of microalgal fatty acids and total carotenoid content in Nitzschia closterium (Bacillariophyceae) and Phaeodactylum tricornutum (Chrysophyceae). Food Chem. 129 (3), 783–791.

Huang, J.J., Cheung, P.C., 2011. +UVA treatment increases the degree of unsaturation of microalgal fatty acids and total carotenoid content in Nitzschia closterium (Bacillariophyceae) and Thalassiosira zhangjiangensis (Chrysophyceae). Food Chem. 129 (3), 783–791.

Shapiro, I.P., Masliah, E., Saitoh, T., 1991. Altered protein tyrosine phosphorylation in Alzheimer’s disease. J. Neurochem. 56 (4), 1154–1162.

Aliev, G., Obrenovich, M.E., Smith, M.A., Perry, G., 2003. Hypoperfusion, mitochondria failure, oxidative stress, and alzheimer disease. J. Biomed. Biotechnol. 2003 (3), 162–163.

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., Jones, E., 2011. +UVA treatment increases the degree of unsaturation of microalgal fatty acids and total carotenoid content in Nitzschia closterium (Bacillariophyceae) and Phaeodactylum tricornutum (Chrysophyceae). Food Chem. 129 (3), 783–791.

Huang, J.J., Cheung, P.C., 2011. +UVA treatment increases the degree of unsaturation of microalgal fatty acids and total carotenoid content in Nitzschia closterium (Bacillariophyceae) and Thalassiosira zhangjiangensis (Chrysophyceae). Food Chem. 129 (3), 783–791.

Shapiro, I.P., Masliah, E., Saitoh, T., 1991. Altered protein tyrosine phosphorylation in Alzheimer’s disease. J. Neurochem. 56 (4), 1154–1162.

Obrenovich, M.E., Smith, M.A., Perry, G., 2003. Hypoperfusion, mitochondria failure, oxidative stress, and alzheimer disease. J. Biomed. Biotechnol. 2003 (3), 162–163.

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., Jones, E., 2011. +UVA treatment increases the degree of unsaturation of microalgal fatty acids and total carotenoid content in Nitzschia closterium (Bacillariophyceae) and Phaeodactylum tricornutum (Chrysophyceae). Food Chem. 129 (3), 783–791.